High-Dose Steroid for Hip Arthroplasty Patients Expected to Have Postoperative Pain
CompletedPhase 4NCT03763760
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of the Study is to test a higher dose of steroids(Dexamethasone) given just prior to surgery in the setting of Fast-Track Hip-surgery with Arthroplasty in a group of expected High Pain Responders and the effect on postoperative pain and postoperative inflammation.
Study details
- Official title
- High-Dose Steroids in High Pain Responders Undergoing Total Hip-arthroplasty: A Randomized Double Blinded Controlled Trial
- Conditions
- Postoperative Pain
- Postoperative Nausea and Vomiting
- Hip Osteoarthritis
- Perioperative/Postoperative Complications
- Surgery
- Opioid Use
- Catastrophizing Pain
- Chronic Pain
- Interventions
- Sponsor
- Copenhagen University Hospital, Hvidovre
- Collaborators
- Sygehus Lillebaelt
- Start date
- 2019-01-29
- Primary completion
- 2021-01-01
- Sex
- All
- Age range
- from 40 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age between 40 and 90. * Booked for unilateral Hip-arthroplasty. * Is able to take part in the investigation(selfreported pain and nausea/vomiting) * Understands Danish or English, or has a translator available. * Signed written consent. * A daily use of 30 mg or more of morphine or morphine equivalents . * A pain catastrophizing scale(PCS) score of \>20. Exclusion Criteria: * Insulin-dependent diabetes melitus. * Ongoing treatment with systemic glucocorticoids or immunosuppressing treatment(apart from inhaled glucocorticoids). * Pregnancy/Breastfeeding * Allergies for the investigational drug. * A history of schizophrenia or bipolar diseases, or patients with permanent use of antipsychotic medication.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03763760